ICD 10 CM C83.3 | Description & Clinical Information

ICD 10 C83.3 describes a type of non-Hodgkin lymphoma known as diffuse large B-cell lymphoma (DLBCL), which is characterized by the abnormal multiplication and scattering of B cell lymphocytes throughout various parts of the body, including lymph nodes, skin, digestive system, testes, thyroid, breast, bone, and central nervous system, making it the most common and fast-growing type of NHL.

Official Description Of C83.3

The ICD 10 CM book defines ICD 10 code C83.3 as:

When To Use C83.3

The diagnosis describes by ICD-10-CM C83.3 involves a specific type of non-Hodgkin lymphoma known as diffuse large B-cell lymphoma (DLBCL). This lymphoma manifests in different variations, with some referred to as primary and others named based on the cell of origin involved in the disease. The type and location of DLBCL influence the symptoms and prognosis of the patient.

Usually, the early signs of DLBCL present as painless or painful enlarged lymph nodes in the neck, pelvic region, and the armpits. As the disease progresses, the patient may develop additional symptoms such as fever, unexplained weight loss, profuse sweating during sleep, difficulty breathing, and appetite loss. The healthcare provider makes a definitive diagnosis based on a patient’s history, signs, and symptoms alongside a physical examination.

Blood tests may also be necessary to determine the extent of the disease. Typically, decreased white blood cells (leukopenia) and increased lymphocytes levels are detected. Additionally, a lymph node biopsy diagnostic is performed, with an analysis of the microscopic sample. This procedure is crucial in affirming the prevalence and extent of the disease.

Further diagnostic tests may include kidney function tests, liver function tests, complete blood cell count (CBC), and lactate dehydrogenase (LDH) to assess the magnitude of involvement. Medical imaging tests like CT or PET scans are useful in determining the extent of malignancy and staging the disease.

The treatment of DLBCL depends on the phase and severity of the disease. One of the most accepted treatment regimens for DLBCL is RCHOP therapy, which is a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. In cases of advanced DLBCL where the disease has progressed or recurred, high-dose chemotherapy, combined with stem cell transplantation, is usually considered.

Moreover, the care of patients with DLBCL is complex and involves a team of experts from the medical profession, including hematologists and oncologists. The treatment plan usually depends on the age, health status, and medical history of the patient in addition to other factors.

In conclusion, the ICD-10-CM C83.3 diagnosis code signifies the presence of diffuse large B-cell lymphoma (DLBCL). The diagnosis code underscores the need for a thorough diagnostic process that includes medical history taking, blood tests, and imaging studies. Additionally, the healthcare provider must consider the extent of the disease to develop an appropriate treatment plan for the patient.